Clay Siegall, Life Science Washington via YouTube
February 10, 2022 01:59 PM ESTUpdated 05:09 PM
Pharma

Seagen's stock plunges af­ter re­veal­ing a dis­ap­point­ing out­look for one of its core can­cer drugs

Nicole DeFeudis

Editor

With sales up 38% last year com­pared to 2020, Seagen CEO Clay Sie­gall used the com­pa­ny’s Q4 call to high­light what he called an ex­cep­tion­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times